GnRH Agonist Pretreatment in Hysteroscopic Myomectomy

Surgical Effects of GnRH Agonist Pretreatment on Cold Loop Hysteroscopic Myomectomy.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01873378

Enrollment

Registered

2013-06-10

Start date

2013-01-31

Completion date

2015-08-31

Last updated

2015-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Myoma

Keywords

Uterine myoma, GnRHa, Hysteroscopy, Cold loop

Brief summary

The primary outcome of this study is to assess if the GnRHa administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure. Moreover, we will investigate the intraoperative influence of such pharmacologic therapy in terms of distension liquid absorption and duration of the procedures.

Interventions

DRUGTriptorelin 3.75 mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* submucous myoma diagnosed by vaginal ultrasonography and confirmed by diagnostic hysteroscopy * premenopausal status

Exclusion criteria

* present or past history of cancer * pregnancy * presence of associated multiple polyps * presence of \> 2 myomas * associated nonhysteroscopic surgical procedures

Design outcomes

Primary

Measure	Time frame
To assess if the GnRHa administration before cold loop hysteroscopic myomectomy contributes to accomplish the treatment in only one surgical procedure.	Just finished the surgical procedure.

Secondary

Measure	Time frame
Minutes (surgical procedure time), milliliters (fluid absorption during the procedure).	Just finished the surgical procedure.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026